| On more than one occasion over the past year, recommendations have been submitted to the regulatory authority responsible for pharmaceutical pricing in Hong Kong, proposing that medicines with existing approved indications be permitted to register new indications under a special licensing arrangement. | 이식
> 이식: 간 | 규제 파트너십
> 규제 기관과의 협력 | 5,000 | Regional | Regularly | 115046959426 |
| On more than one occasion over the past year, recommendations have been submitted to the regulatory authority responsible for pharmaceutical pricing in Hong Kong, proposing that medicines with existing approved indications be permitted to register new indications under a special licensing arrangement. | 이식
> 이식: 간 | 규제 파트너십
> 건강기술평가(HTA) 및 급여 검토에 참여 | 5,000 | Regional | Regularly | 115046959426 |
| As an orphan medicinal product for a rare disease, the cost is prohibitively high. Strong representations to this effect have already been made to the Government, the HA [[醫院管理局 – Hospital Authority], and the relevant pharmaceutical manufacturers. | 희귀
> 희귀 질환: 대부분의 유형 | 정책 및 법률에 영향 미치기
> 의료 정책 및 법률에 영향력 행사 | 100 | Regional | Rarely | 115017299676 |
| We suggested a big pharmaceutical company to reduce its selling price as it is not affordable by the patients. | 환자 권익 옹호
> 환자 권익 옹호 | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | 5,000 | Regional | Sometimes | 115004724749 |
| The dual-pricing fees are prohibitively high. | 지정되지 않음
> 지정되지 않음 | 가격 책정 및 affordability 옹호
> 공정한 의약품 가격 책정 옹호 | 1,000 | Regional | Sometimes | 115053340704 |
| We suggested a big pharmaceutical company to reduce its selling price as it is not affordable by the patients. | 환자 권익 옹호
> 환자 권익 옹호 | 가격 책정 및 affordability 옹호
> 제조업체의 판매 가격 인하 요청 | 5,000 | Regional | Sometimes | 115004724749 |
| We suggested a big pharmaceutical company to reduce its selling price as it is not affordable by the patients. | 환자 권익 옹호
> 환자 권익 옹호 | 가격 책정 및 affordability 옹호
> 의약품 가격/의약품 부족 현황 추적 및 모니터링 | 5,000 | Regional | Sometimes | 115004724749 |
| On more than one occasion over the past year, recommendations have been submitted to the regulatory authority responsible for pharmaceutical pricing in Hong Kong, proposing that medicines with existing approved indications be permitted to register new indications under a special licensing arrangement. | 이식
> 이식: 간 | 가격 책정 및 affordability 옹호
> 제품의 급여 목록/국가 처방집 등재 옹호 | 5,000 | Regional | Regularly | 115046959426 |
| We have addressed the issue of treatment options to the health authority. | 시각 장애
> 망막 질환 | 접근 경로 개선
> 의약품/의료서비스에 대한 공평한 접근 촉진 | 1,000 | Local | Sometimes | 119068473108 |
| The cost of rare disease medicines classified as orphan drugs is extremely high. | 희귀
> 희귀 질환: 대부분의 유형 | 접근 경로 개선
> 희귀/초희귀 치료제 접근성 개선 | 100 | Regional | Rarely | 115017299676 |
| As an orphan medicinal product for a rare disease, the cost is prohibitively high. Strong representations to this effect have already been made to the Government, the HA [[醫院管理局 – Hospital Authority], and the relevant pharmaceutical manufacturers. | 희귀
> 희귀 질환: 대부분의 유형 | 접근 경로 개선
> 희귀/초희귀 치료제 접근성 개선 | 100 | Regional | Rarely | 115017299676 |
| The pricing of so-called 'orphan drugs' — medications designated for the treatment of rare diseases — is prohibitively expensive. | 신경학적
> 신경섬유종증(NF) | 접근 경로 개선
> 희귀/초희귀 치료제 접근성 개선 | 100 | Regional | Rarely | 115018622259 |
상호작용
활동 및 옹호
2 멘션
